North America Anthelmintic Drugs Market Analysis from 2022 to 2034 Containing Market Size, Share along with its CAGR, Forecast and Trends
Top Countries — Revenue
Access the full forecast model.
Country-level data · Company profiles · Editable dataset · Analyst consultation included.
North America Anthelmintic Drugs Market Analysis — Presence
Geographical Analysis
Click countries to exploreCountry Analysis
North America Anthelmintic Drugs Market Analysis 2026
| Region / Country | 2021 (A) | 2025 (A) | 2033 (P) | CAGR |
|---|---|---|---|---|
| North America Anthelmintic Drugs Total | xxxx | xxxx | xxxx | 2.5% |
| United States | xxxx | xxxx | xxxx | xxxx |
| Canada | xxxx | xxxx | xxxx | xxxx |
| Mexico | xxxx | xxxx | xxxx | xxxx |
A = Actual · E = Estimated · P = Projected · 🔒 Locked values require full access. Click headers to sort.
Unlock full regional dataset →Segmentation Analysis
Drug Class breakdown · Illustrative 2025 shares shown free · Full-period forecast in paid report.
Disclaimer: The charts and graphs are for illustrative purposes only and do not represent actual market values. To access accurate quantitative data, please request a paid report or request free sample.
To learn more about market share and segmentation, request the free sample pages.
Competitor Analysis
Competitive Landscape of the Anthelmintic Drugs Market
The major players adopt inventive strategies quickly to gain an edge over their rivals and take a major market share. To serve a sizable customer base and obtain a competitive advantage, major players in the Anthelmintic Drugs market place an enormous value on extending their unique offers.
Anthelmintic Drugs Industry News
- February 2021, Merck said that the FDA had approved KOMBITRIM, their newest oral combination medication, to treat certain worm-caused parasitic diseases in both adults and children. Ivermectin and albendazole, two popular anthelmintic drugs, are combined in a pill called KOMBITRIM.
(Source: www.merck.com/news/merck-statement-on-ivermectin-use-during-the-covid-19-pandemic/)
| Top Companies (In no particular order) | 2022 (A) | 2023 (A) | 2024 (A) | 2025 (A) |
|---|---|---|---|---|
| Company 1 | ••• | ••• | ••• | ••• |
| Company 2 | ••• | ••• | ••• | ••• |
| Company 3 | ••• | ••• | ••• | ••• |
| Company 4 | ••• | ••• | ••• | ••• |
| Company 5 | ••• | ••• | ••• | ••• |
We Provide Regional Breakdown of this Companies and Company specific to any Country, Region, Product/ service as well. We cover market share analysis for publicly listed companies as well as privately held companies, subject to data availability.
Request company profile for validation →Report Scope & Analysis
According to Cognitive Market Research, the global Anthelmintic Drugs market size was estimated at USD 1121.5 Million out of which North America held the major market of more than 40% of the global revenue with a market size of USD 448.60 million in 2023 and will grow at a compound annual growth rate (CAGR) of 2.5% from 2023 to 2030.The market for anthelmintic drugs is expanding rapidly in North America due to factors such as a developed healthcare system, rising public awareness of parasitic illnesses, and a focus on preventative healthcare. The veterinary industry's need for anthelmintic medications to treat parasitic worm diseases in animals is a significant factor driving this rise. All things considered, North America's proactive approach to the treatment of people and animals places the continent in a position to significantly shape the market for anthelmintic drugs by highlighting the significance of preventative measures in the fight against helminthic infections and upholding public health standards.
- According to Cognitive Market Research, the US had a major share in the Anthelmintic Drugs market with a market size of USD 353.95 million in 2023 and is projected to grow at a CAGR of 2.3% during the forecast period. This is majorly due to its strict regulations.
- The Canada Anthelmintic Drugs market had a market share of USD 53.83 million in 2023 and is projected to grow at a CAGR of 3.3% during the forecast period. This is due to the focus on preventive healthcare.
- The Mexico Anthelmintic Drugs market is projected to witness growth at a CAGR of 3.0% during the forecast period with a market size of USD 40.82 million in 2023.
The medical devices and consumables industry is growing rapidly, driven by aging populations, rising healthcare spending, and supportive regulations, boosting demand for implants, assistive tech, and home monitoring. Challenges include strict regulations, high R&D costs, and supply chain risks, but opportunities lie in emerging markets, health-tech partnerships, and eco-friendly devices. Key trends such as AI, precision medicine, and sustainable innovations are transforming healthcare and accelerating market growth.
Analyst Conclusion
Author's Say's
- North America Anthelmintic Drugs held the major market of more than 40% of the global revenue with a market size of USD 448.60 million in 2023 and will grow at a compound annual growth rate (CAGR) of 2.5% from 2023 to 2030.
- Development of new drugs and drug combinations, there is an increasing need for Anthelmintic Drugs.
Supriya is a Team Lead at Cognitive Market Research & Consulting, leading research initiatives and strategic intelligence projects across the Healthcare, Pharmaceuticals, and Medical Devices & Consumables sectors. With more than two years of experience in market research and data analysis, she plays a key role in helping organizations navigate complex healthcare ecosystems, identify emerging opportunities, and make informed business decisions through data-driven insights and market intelligence.
Combining expertise in both primary and secondary research methodologies with a strong academic foundation in Marketing and Finance, Supriya oversees the execution of market assessments, competitive intelligence studies, forecasting models, stakeholder interviews, trend analysis, and custom consulting engagements. She collaborates with healthcare providers, pharmaceutical manufacturers, medical device companies, industry experts, and other key stakeholders to gather firsthand market perspectives while validating findings through extensive research. Her ability to interpret clinical, commercial, and market data enables clients to better understand industry developments, regulatory influences, innovation trends, and competitive dynamics.
In her leadership role, she manages end-to-end research projects and guides cross-functional teams in delivering high-quality market reports, consulting solutions, and strategic studies. Her expertise in market estimation, forecasting, and analytical modeling helps organizations evaluate market potential, assess growth opportunities, strengthen competitive positioning, and support strategic planning initiatives. By transforming complex healthcare and life sciences data into actionable business intelligence, she enables clients to make confident decisions in rapidly evolving market environments.
Driven by a passion for healthcare innovation and continuous professional development, Supriya remains committed to staying ahead of industry trends, technological advancements, and changing market conditions. Her leadership, analytical mindset, and dedication to research excellence help organizations mitigate risks, capitalize on emerging opportunities, and achieve sustainable growth across the global healthcare and life sciences landscape.
Frequently Asked Questions
★ Reviews
Rate this report
North America Anthelmintic Drugs Market Analysis — Table of Contents
- This is just a redacted sample pages of the actual deliverable report and only for representative purposes
- Charts/Graphs/Numbers/data are only for Representative purposes and do not depict actual statistics.
- The table of Contents differs according to the user License selection. Current Displayed TOC is for the Corporate User License Report Edition. TOC Customization options: Add or Remove section/s Or chapter/s from the report.
- Specific Tables, Graphs, Sections, and Chapters can be ordered at a discounted price.
- If applicable; On Request Volume Data will also be provided (at an Additional Cost).
Report Scope
| Drug Class | Benzimidazoles, Piperazine, Others |
|---|---|
| Application | Human, Animal |
| Route of Administration | Oral, Injectable |
| Distribution Channel | Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Veterinary Pharmacies, Veterinary Hospitals & Clinics |
| List of Competitors | GlaxoSmithKline plc , Johnson & Johnson , Merck & Co. Inc. , Bayer AG , Cipla Ltd. , Sun Pharmaceutical Industries Ltd. , Teva Pharmaceutical Industries Limited , Reese Pharmaceutical Company , Zydus Lifesciences Limited |
Chapter 1. Competitor Analysis (Subject to Data Availability (Private Players))
- 1.1 Top Competitors Analysis
- 1.1.1 Top Players Ranking 2024
- 1.1.2 New Product Launch Analysis
- 1.2 Company Profile (Data Subject to Availability) Sample Format
- 1.2.1 GlaxoSmithKline plc
- 1.2.1.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
- 1.2.1.2 Business Overview
- 1.2.1.3 R&D Investment (Subject to data availability)
- 1.2.1.4 Financials (Subject to data availability)
- 1.2.1.5 Product Types Specification
- 1.2.1.6 Business Strategy
- 1.2.1.7 Recent Developments
- 1.2.1.8 Management Change
- 1.2.1.9 S.W.O.T Analysis
- 1.2.2 Johnson & Johnson
- 1.2.2.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
- 1.2.2.2 Business Overview
- 1.2.2.3 R&D Investment (Subject to data availability)
- 1.2.2.4 Financials (Subject to data availability)
- 1.2.2.5 Product Types Specification
- 1.2.2.6 Business Strategy
- 1.2.2.7 Recent Developments
- 1.2.2.8 Management Change
- 1.2.2.9 S.W.O.T Analysis
- 1.2.3 Merck & Co. Inc.
- 1.2.3.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
- 1.2.3.2 Business Overview
- 1.2.3.3 R&D Investment (Subject to data availability)
- 1.2.3.4 Financials (Subject to data availability)
- 1.2.3.5 Product Types Specification
- 1.2.3.6 Business Strategy
- 1.2.3.7 Recent Developments
- 1.2.3.8 Management Change
- 1.2.3.9 S.W.O.T Analysis
- 1.2.4 Bayer AG
- 1.2.4.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
- 1.2.4.2 Business Overview
- 1.2.4.3 R&D Investment (Subject to data availability)
- 1.2.4.4 Financials (Subject to data availability)
- 1.2.4.5 Product Types Specification
- 1.2.4.6 Business Strategy
- 1.2.4.7 Recent Developments
- 1.2.4.8 Management Change
- 1.2.4.9 S.W.O.T Analysis
- 1.2.5 Cipla Ltd.
- 1.2.5.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
- 1.2.5.2 Business Overview
- 1.2.5.3 R&D Investment (Subject to data availability)
- 1.2.5.4 Financials (Subject to data availability)
- 1.2.5.5 Product Types Specification
- 1.2.5.6 Business Strategy
- 1.2.5.7 Recent Developments
- 1.2.5.8 Management Change
- 1.2.5.9 S.W.O.T Analysis
- 1.2.6 Sun Pharmaceutical Industries Ltd.
- 1.2.6.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
- 1.2.6.2 Business Overview
- 1.2.6.3 R&D Investment (Subject to data availability)
- 1.2.6.4 Financials (Subject to data availability)
- 1.2.6.5 Product Types Specification
- 1.2.6.6 Business Strategy
- 1.2.6.7 Recent Developments
- 1.2.6.8 Management Change
- 1.2.6.9 S.W.O.T Analysis
- 1.2.7 Teva Pharmaceutical Industries Limited
- 1.2.7.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
- 1.2.7.2 Business Overview
- 1.2.7.3 R&D Investment (Subject to data availability)
- 1.2.7.4 Financials (Subject to data availability)
- 1.2.7.5 Product Types Specification
- 1.2.7.6 Business Strategy
- 1.2.7.7 Recent Developments
- 1.2.7.8 Management Change
- 1.2.7.9 S.W.O.T Analysis
- 1.2.8 Reese Pharmaceutical Company
- 1.2.8.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
- 1.2.8.2 Business Overview
- 1.2.8.3 R&D Investment (Subject to data availability)
- 1.2.8.4 Financials (Subject to data availability)
- 1.2.8.5 Product Types Specification
- 1.2.8.6 Business Strategy
- 1.2.8.7 Recent Developments
- 1.2.8.8 Management Change
- 1.2.8.9 S.W.O.T Analysis
- 1.2.9 Zydus Lifesciences Limited
- 1.2.9.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
- 1.2.9.2 Business Overview
- 1.2.9.3 R&D Investment (Subject to data availability)
- 1.2.9.4 Financials (Subject to data availability)
- 1.2.9.5 Product Types Specification
- 1.2.9.6 Business Strategy
- 1.2.9.7 Recent Developments
- 1.2.9.8 Management Change
- 1.2.9.9 S.W.O.T Analysis
- 1.2.1 GlaxoSmithKline plc
- 1.1 Top Competitors Analysis
Chapter 2. Global Anthelmintic Drugs Market Analysis
- 2.1 Global Anthelmintic Drugs Market Analysis
- 2.2 Global Anthelmintic Drugs Market Analysis by Drug Class
- 2.3 Global Anthelmintic Drugs Market Analysis by Application
- 2.4 Global Anthelmintic Drugs Market Analysis by Route of Administration
- 2.5 Global Anthelmintic Drugs Market Analysis by Distribution Channel
Chapter 3. North America Anthelmintic Drugs Market Analysis
- 3.1 North America Anthelmintic Drugs Market Analysis
- 3.2 North America Anthelmintic Drugs Market Analysis by Country
- 3.3 North America Anthelmintic Drugs Market Analysis by Drug Class
- 3.4 North America Anthelmintic Drugs Market Analysis by Application
- 3.5 North America Anthelmintic Drugs Market Analysis by Route of Administration
- 3.6 North America Anthelmintic Drugs Market Analysis by Distribution Channel
- 3.7 North America Anthelmintic Drugs Market Analysis by Key Players
Chapter 4. United States Anthelmintic Drugs Market Analysis
- 4.1 United States Anthelmintic Drugs Market Analysis
- 4.2 United States Anthelmintic Drugs Market Analysis by Drug Class
- 4.3 United States Anthelmintic Drugs Market Analysis by Application
- 4.4 United States Anthelmintic Drugs Market Analysis by Route of Administration
- 4.5 United States Anthelmintic Drugs Market Analysis by Distribution Channel
- 4.6 United States Anthelmintic Drugs Market Analysis by Key Players
Chapter 5. Canada Anthelmintic Drugs Market Analysis
- 5.1 Canada Anthelmintic Drugs Market Analysis
- 5.2 Canada Anthelmintic Drugs Market Analysis by Drug Class
- 5.3 Canada Anthelmintic Drugs Market Analysis by Application
- 5.4 Canada Anthelmintic Drugs Market Analysis by Route of Administration
- 5.5 Canada Anthelmintic Drugs Market Analysis by Distribution Channel
- 5.6 Canada Anthelmintic Drugs Market Analysis by Key Players
Chapter 6. Mexico Anthelmintic Drugs Market Analysis
- 6.1 Mexico Anthelmintic Drugs Market Analysis
- 6.2 Mexico Anthelmintic Drugs Market Analysis by Drug Class
- 6.3 Mexico Anthelmintic Drugs Market Analysis by Application
- 6.4 Mexico Anthelmintic Drugs Market Analysis by Route of Administration
- 6.5 Mexico Anthelmintic Drugs Market Analysis by Distribution Channel
- 6.6 Mexico Anthelmintic Drugs Market Analysis by Key Players
Chapter 7. Drug Class Analysis
- 7.1 Benzimidazoles
- 7.2 Piperazine
- 7.3 Others
Chapter 8. Application Analysis
- 8.1 Human
- 8.2 Animal
Chapter 9. Route of Administration Analysis
- 9.1 Oral
- 9.2 Injectable
Chapter 10. Distribution Channel Analysis
- 10.1 Hospital Pharmacies
- 10.2 Retail Pharmacies
- 10.3 Online Pharmacies
- 10.4 Veterinary Pharmacies
- 10.5 Veterinary Hospitals & Clinics
Chapter 11. Qualitative Analysis (Subject to Data Availability)
- 11.1 Market Drivers
- 11.2 Market Restraints
- 11.3 Market Trends
- 11.4 Market Opportunity
- 11.5 Technological Road Map (Subject to Data Availability)
- 11.6 Product Life Cycle (Subject to Data Availability)
- 11.7 Customer and Buyer Behavior Analysis
- 11.7.1 Digital Engagement, Customer Experience & Relationship Analysis
- 11.7.2 Customer Buying Behavior & Purchase Decision Analysis
- 11.7.3 Vendor Selection, Supplier Preferences & Future Demand Trends
- 11.7.4 Pricing, Affordability & Value Perception Analysis
- 11.7.5 Customer Segmentation & Demand Pattern Analysis
- 11.8 Industrial Chain Analysis (Subject to Data Availability)
- 11.8.1 Industry Chain Analysis
- 11.8.2 Manufacturing Cost Analysis
- 11.8.3 Supply Side Analysis
- 11.8.3.1 Raw Material Analysis
- 11.8.3.2 Raw Material Procurement Analysis
- 11.8.3.3 Raw Material Price Trend Analysis
- 11.9 PESTEL Analysis
- 11.9.1 Environmental Factors
- 11.9.2 Legal Factors
- 11.9.3 Technological Factors
- 11.9.4 Economic Factors
- 11.9.5 Political Factors
- 11.9.6 Social Factors
- 11.10 Porter’s Five Forces Analysis
- 11.10.1 Degree of Competition
- 11.10.2 Threat of Substitutes
- 11.10.3 Threat of New Entrants
- 11.10.4 Bargaining Power of Buyers
- 11.10.5 Bargaining Power of Suppliers
- 11.11 Patent Analysis (Subject to Data Availability)
- 11.12 ESG Analysis
- 11.13 Geopolitical Outlook
- 11.13.1 Global Power Realignment & Strategic Alliances
- 11.13.2 Geopolitical Risk Landscape & Conflict Hotspots
- 11.13.3 International Trade Relations & Market Access Environment
- 11.13.4 Regulatory & Policy Shifts Impacting Cross-Border Operations
- 11.13.5 Supply Chain Resilience, Localization & Resource Nationalism
- 11.13.6 Technology Sovereignty & Digital Geopolitics
- 11.13.7 Strategic Implications for Investment, Growth & Market Entry
- 11.14 AI & Market Transformation
- 11.14.1 Competitive Landscape Disruption & Strategic Shifts
- 11.14.2 AI-Driven Transformation of Industry Value Chain
- 11.14.3 Evolution of Business Models & Revenue Streams
- 11.14.4 AI-Driven Product, Service & Innovation Transformation
- 11.14.5 Customer Behavior, AI Adoption & Future Market Evolution
Chapter 12. Research Findings
- 12.1 Key Takeaways
- 12.2 Analyst Point of View
- 12.3 Assumptions and Acronyms
Chapter 13. Research Methodology and Sources
- 13.1 Primary Data Collection
- 13.1.1 Steps for Primary Data Collection
- 13.1.1.1 Identification of KOL
- 13.1.2 Backward Integration
- 13.1.3 Forward Integration
- 13.1.4 How Primary Research Help Us
- 13.1.5 Modes of Primary Research
- 13.1.1 Steps for Primary Data Collection
- 13.2 Secondary Research
- 13.2.1 How Secondary Research Help Us
- 13.2.2 Sources of Secondary Research
- 13.3 Data Validation
- 13.3.1 Data Triangulation
- 13.4 Data Representation
- 13.1 Primary Data Collection
Athenaeum AI Dashboard
Our Proprietary Methodology
Cognitive Market Research and Consulting "The Full Truth" methodology — a rigorous triangulation process that combines primary research, secondary validation, and expert calibration. Implemented by Supriya Yadav and team for the North America Anthelmintic Drugs Market Analysis Market analysis.
Primary Intelligence Gathering
Direct interviews with 50+ industry stakeholders including manufacturers, distributors, end-users, and regulatory bodies across all six regions.
Secondary Data Triangulation
Cross-referencing against trade databases, customs records, financial filings, patent databases, and verified industry publications.
Expert Validation Protocol
Each data point undergoes validation by minimum two independent domain experts with 15+ years of industry experience.
Athenaeum AI Processing
Our proprietary AI platform aggregates, normalizes, and identifies patterns across 10,000+ data points to surface non-obvious insights.
Editorial & QA Review
Final review by senior analysts ensures accuracy, coherence, and actionability of all insights and recommendations.
Data Assurance Metrics
Analytical Coverage
To maintain the integrity of our proprietary methodology and protect our elite expert network, specific source disclosures are reserved for full-access partners. Our research framework is anchored by a 70:30 primary-to-secondary ratio, ensuring your strategy is driven by real-time market intelligence rather than recycled, publicly available, or AI-generated data. Every deliverable includes an exhaustive source directory and grants direct analyst access.
Sources from the Medical Devices and Consumables Industry
The Three Pillars of End-to-End Market Research Services
We don't just hand over data. We partner with your team across three integrated service lines — each designed to give you decision-grade intelligence on the North America Anthelmintic Drugs Market Analysis market.
Market Survey
Structured primary research across both B2B and B2C channels. We design and execute custom surveys targeting manufacturers, distributors, procurement heads, and end-consumers in the north america anthelmintic drugs market analysis ecosystem — validated by our global panel of 10,000+ industrial respondents.
- Buyer intent & sentiment analysis
- Purchase cycle mapping
- Price sensitivity research
- Channel preference profiling
- Competitive perception study
Customized Market Data & Reports
Choose from our ready-to-access 8th Edition report or commission a fully customized dataset tailored to your exact strategic questions. Cross-splits, custom geographies, proprietary segmentation — we build the intelligence asset your board actually needs.
- Ready syndicate report
- Custom data scope & segmentation
- Excel quantitative models
- Board-ready PPT with key findings
- Secure cloud portal access
Strategic Consultation
Every survey and every report comes with dedicated analyst consultation. Our senior research team walks your leadership through findings, answers strategic questions in real-time, and helps translate data into your next board presentation or investment thesis.
- Dedicated analyst assigned to you
- Live walkthrough of findings
- Strategic Q&A sessions
- Go-to-market recommendations
- NDA-protected engagement
Customize This Report
Tell us the specific segments, regions, or companies you need — and we will tailor the deliverable to your requirements.
